

PRODUCT DATA SHEET

Bioworld Technology CO., Ltd.



Vasohibin (R302) Peptide

Cat No.: BS9217P

Background

Angiogenesis is mainly regulated by the balance of several different pro-angiogenic stimulators, such as vascular endothelial growth factor (VEGF) and a diverse group of endogenous inhibitors that are extrinsic to endothelial cells. Vasohibin is a secreted protein that is induced by a specific, self-regulating, feedback inhibition response to inhibit angiogenesis in an auto-crine manner. It inhibits proliferation, migration, and network formation by endothelial cells. This function is specific for endothelial cells as it does not affect migration in other cell types. Vasohibin is primarily expressed in endothelial of the brain and placental tissues with highest abundance in fetal organs. VEGF and fibroblast growth factor 2 upregulate the expression of Vasohobin. In vitro, Vasohibin does not affect cancer cell proliferation, but does inhibit tumor growth and angiogenesis.

Swiss-Prot

Q7L8A9

Applications

Blocking

Specificity

This peptide can be used with studies using BS9217 Vasohibin (R302) pAb.

Purification & Purity

Synthetic peptide Vasohibin (R302). (Note: the amino acid sequence is proprietary). The purity is > 98%.

Product

1 mg/ml in DI water.

Storage & Stability

Store at 4 °C short term. Aliquot and store at -20 °C long term. Avoid freeze-thaw cycles.

Research Use

For research use only, not for use in diagnostic procedure.

Bioworld Technology, Inc.
1660 South Highway 100, Suite 500 St. Louis Park, MN
55416, USA. Email: info@bioworlde.com
Tel: 6123263284 Fax: 6122933841

Bioworld technology, co, Ltd.
No 9, weidi road Qixia District Nanjing, 210046,
P, R.China. Email: info@biogot.com
Tel: +86-025-68037686 Fax: +86-025-68035151